

**HHS PUBLIC ACCESS**

Author manuscript

Cancer Res. Author manuscript; available in PMC 2017 December 01.

Published in final edited form as:

Cancer Res. 2016 December 1; 76(23): 6924–6936. doi:10.1158/0008-5472.CAN-16-1597.**Destabilization of fatty acid synthase by acetylation inhibits de novo lipogenesis and tumor cell growth****Huai-Peng Lin¹, Zhou-Li Cheng¹, Ruo-Yu He², Lei Song³, Meng-Xin Tian⁴, Li-Sha Zhou¹, Beezly S. Groh⁷, Wei-Ren Liu⁴, Min-Biao Ji², Chen Ding^{1,3}, Ying-Hong Shi⁴, Kun-Liang Guan^{1,5,*}, Dan Ye^{1,6,*}, and Yue Xiong^{1,7,*}**

¹Molecular and Cell Biology Lab, Institute of Biomedical Sciences, Shanghai Medical College; Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, and Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences; State Key Laboratory of Genetic Engineering, Collaborative Innovation Center of Genetics and Development, School of Life Sciences, Fudan University, Shanghai 200032, China

²State Key Laboratory of Surface Physics and Department of Physics, Fudan University, Shanghai, 200433, China

³State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, National Center for National Center for Protein Science (The PHOENIX Center), Beijing 102206, China

⁴Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032, China

⁵Department of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, California 92093

⁶Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China

⁷Lineberger Comprehensive Cancer Center, Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, North Carolina 27599

Abstract

Fatty acid synthase (FASN) is the terminal enzyme in de novo lipogenesis and plays a key role in cell proliferation. Pharmacological inhibitors of FASN are being evaluated in clinical trials for treatment of cancer, obesity and other diseases. Here we report a previously unknown mechanism of FASN regulation involving its acetylation by KAT8 and its deacetylation by HDAC3. FASN acetylation promoted its degradation via the ubiquitin-proteasome pathway. FASN acetylation enhanced its association with the E3 ubiquitin-ligase TRIM21. Acetylation destabilized FASN and resulted in decreased de novo lipogenesis and tumor cell growth. FASN acetylation was frequently reduced in human hepatocellular carcinoma samples, which correlated with increased HDAC3

*Correspondence to: kuguan@ucsd.edu (K.-L.G.); [yedat@fudan.edu.cn](mailto:yedan@fudan.edu.cn) (D.Y.); yxiong@email.unc.edu (Y.X.).

Conflict of Interest

No potential conflict of interest was disclosed.

expression and FASN protein levels. Our results suggest opportunities to target FASN acetylation as an anticancer strategy.

Keywords

FASN; *de novo* lipogenesis; acetylation; ubiquitylation

Introduction

In *de novo* lipogenesis, fatty acid synthase (FASN) catalyzes the synthesis of palmitate from acetyl-CoA and malonyl-CoA, in the presence of NADPH as a reducing equivalent. FASN expression is commonly low in normal and non-proliferating cells, which typically import lipids from the extracellular milieu. In contrast, actively proliferating cells, especially tumor cells, have increased demands for lipids, which is highly dependent on *de novo* synthesis. Accordingly, FASN is frequently up-regulated in many types of tumors, such as breast, prostate, liver, colon, and ovarian cancers (1–6). Moreover, increased FASN expression is linked to chemoresistance, tumor metastasis, and poorer prognosis in numerous types of cancers (7–10). These observations suggest that FASN plays an important role in affecting tumor metabolism and FASN-catalyzed *de novo* lipid synthesis could be a rational therapeutic target for cancer. Extensive efforts have been invested into the development of FASN inhibitors for treating cancer, as well as non-proliferative disease such as obesity. For instance, Cerulenin and its semi-synthetic derivate C75, both of which inhibit the condensation reaction of fatty acid synthesis, can induce apoptosis in breast cancer cells and delay tumor progression in a xenograft model of ovarian cancer (11, 12); Orlistat, which inhibits the release of palmitate (13), can induce apoptosis, inhibit cell proliferation, and suppress tumor growth in prostate cancer cells (14). However, many current FASN inhibitors exhibit strong toxicity in preclinical and clinical trials (15), underscoring the importance of identifying new strategies to target FASN.

Regulation of FASN has been studied extensively and its regulation at the level of transcription has been the primary focus to date. Human *FASN* gene expression is controlled by multiple transcription factors, including upstream stimulatory factor (USF), sterol regulatory element binding protein-1 (SREBP-1), and carbohydrate responsive element-binding protein (ChREBP) (16–18). It has been reported that hypoxia, which is a common microenvironment inside solid tumors, induces SREBP-1 expression and increases *FASN* transcription in cultured human breast cancer cells (19). Insulin, an important metabolism and energy regulator, triggers *FASN* mRNA expression via USF and SREBP-1 recruitment to *FASN* promoter in *Drosophila* SL2 cells and mouse 3T3L1 adipocytes (20–22). Moreover, *FASN* mRNA expression is up-regulated by epidermal growth factor (EGF) in cultured human prostate cancer cells (23) and in the liver of rats fed a carbohydrate/protein diet (24). In addition, *FASN* mRNA expression can also be down-regulated in mouse livers by glucagon, an antagonistic hormone of insulin (25). Furthermore, polyunsaturated fatty acids and leptin can suppress *FASN* mRNA expression via impairing the recruitment of SREBP-1 and other nuclear factors to *FASN* promoter in cultured breast cancer cells (26)

and in rat hepatocytes and adipocytes (27). In contrast to the transcriptional regulation of *FASN*, much less is known about its post-translational regulation.

As an evolutionarily conserved protein post-translational modification, acetylation regulates a wide range of biological processes—gene transcription and metabolism, in particular (28, 29). Several acetylome studies have identified more than 15,000 acetylation sites on >4500 proteins, including *FASN* (29–32). In this study, we investigate the regulatory mechanism and functional consequence of *FASN* acetylation.

Materials and Methods

In vivo ubiquitylation assay

In vivo ubiquitylation assay was performed as described previously (33, 34). Briefly, cells were harvested at 36 hours after transfection and then lysed in 1% SDS (0.5 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 1.0 mM DTT) with protease and phosphatase inhibitor cocktail, and then immunoprecipitated in 0.1% SDS by dilution. Analyses of ubiquitylation were determined by Western blot.

Cell culture

HEK293T, HCT116 and ZR-75-30, which have been used in our present study, were obtained from the American Type Culture Collection (ATCC) in 2015, where they were characterized by Mycoplasma detection, DNA fingerprinting, isozyme detection, and cell vitality detection. HEK293T, HCT116, and ZR-75-30 cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen), McCoy's 5A Medium (Sigma), and RPMI 1640 medium (Sigma), respectively, supplemented with 10% fetal bovine serum (Gibco) in the presence of 100 units/ml penicillin and 100 µg/ml streptomycin at 37°C with 5% CO₂. And Cells were immediately stored in liquid nitrogen till use. A new frozen vial of the same batch of cells was re-started every 2–3 months.

FASN enzyme activity assay

FASN enzyme activity was determined as described previously (4). Briefly, the reaction mixture consisted of 150 µg particle-free supernatant, 200 mM potassium phosphate buffer (pH 6.6), 1 mM dithiothreitol, 1 mM EDTA, 0.24 mM NADPH and 30 µM acetyl-CoA (Sigma) in a total volume of 300 µL. Reactions were initiated by adding 50 µM of malonyl-CoA (Sigma) and analyzed at 25°C. Activities were measured spectrophotometrically by recording oxidation of NADPH at A340nm (HITACH F-4600 fluorescence spectrophotometer). Rates were corrected for the background rate of NADPH oxidation in the presence of acetyl-CoA. *FASN* activity was calculated in nM NADPH oxidized min⁻¹mg protein⁻¹.

Measurement of cellular lipid content

HCT116 cells were seeded on a microscope cover glass in a 35 mm culture plate at a density of 1×10⁶ cells per well. Cells were washed with PBS, and then subjected to a hyperspectral SRS microscope to measure biochemical components. Detailed setup of the SRS microscope has been described previously (35), except that the 2.3 MHz acousto-optic was replaced by a

20 MHz electro-optic modulator. Images (512×512 pixels) were sequentially acquired via the layer by layer scanning model (step size $1 \mu\text{m}$) under frequencies of 2850 cm^{-1} (lipid) and 2928 cm^{-1} (protein), and then reconstructed into two 3D images. The intensity of pixels in 3D images was regarded as the quantity of lipids or proteins and added together after the background was eliminated. Lipid contents were normalized to protein contents in each image. All data were processed using Matlab software.

Cell proliferation analysis

HCT116 or ZR-75-30 stable cells were seeded in 6-well plates at a density of 1×10^5 cells per well. Culture medium was refreshed every day. RGFP966 ($10 \mu\text{M}$) was added into the culture medium at day 1, and refreshed every day. Cell numbers were counted every day over a period of 5 days.

Human Hepatocellular Carcinoma (HCC) cancer samples

Following physician-obtained informed consent from patients, HCC cancer samples were collected by the Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University. The procedures related to human subjects were approved by the Ethics Committee of the Institutes of Biomedical Sciences (IBS), Fudan University.

Statistics

Statistical analyses were performed with a two-tailed unpaired Student's *t*-test, except when indicated. All data shown represent the results obtained from triplicated independent experiments (mean \pm S.D.). The values of $P < 0.05$ were considered statistically significant.

Results

Acetylation promotes FASN protein degradation

Multiple acetylated lysine residues were identified in FASN by mass spectrometry (30–32). Western blotting with a pan anti-acetyl lysine antibody demonstrated that Flag-tagged FASN was indeed acetylated, and its acetylation increased by 2.2-fold in HEK293T cells after combined treatment with nicotinamide (NAM), an inhibitor of the SIRT family deacetylases (36), and trichostatin A (TSA), an inhibitor of histone deacetylase (HDAC) I and II (37) (Fig. 1A). When FASN-overexpressing cells were separately treated with either NAM or TSA, the acetylation level of FASN-Flag was increased by TSA (2.4-fold), but not by NAM (1.1-fold), suggesting that FASN is deacetylated by a HDAC family deacetylase. In agreement, acetylation of endogenous FASN increased by >2 -fold after TSA treatment in three different cell types, HEK293T, HCT116, and ZR-75-30 cells (Figs. 1B and 1C). Notably, TSA-dependent increase in FASN acetylation was accompanied by decreased FASN protein levels (Figs. 1D and 1E). *FASN* mRNA expression was, however, either unaffected (HEK293T and HCT116 cells) or even up-regulated (ZR-75-30 cells) by TSA treatment (Fig. 1F). Together, these results suggest that acetylation may promote FASN protein degradation.

Acetylation promotes FASN degradation via the ubiquitin-proteasome pathway

Inhibition of protein synthesis with cycloheximide (CHX) demonstrated that FASN is a rather stable protein in HCT116 cells with an approximate half-life of 11 hours (Fig. 2A). FASN half-life was reduced to ~7 hours by TSA treatment in HCT116 cells (Fig. 2A). Likewise, FASN half-life was also shortened by 4 hours after TSA treatment in HEK293T cells (Fig. S1A), suggesting that acetylation destabilizes FASN protein.

In eukaryotes, there are two major pathways by which cellular proteins are degraded—the ubiquitin-proteasome pathway and the autophagy-lysosome pathway. Treatment with Leupeptin, an inhibitor of lysosomal degradation, did not increase FASN protein in HEK293T cells (Fig. S1B). In contrast, treatment with the proteasome inhibitor MG132 increased FASN protein in HEK293T cells (Fig. 2B). Importantly, while inhibition of HDAC by TSA decreased FASN protein by 40% (Fig. 2C, comparing lane 1 to lane 2), this decrease was restored by the treatment of cells with MG132, an inhibitor of 26S proteasome (comparing lane 2 to lane 3). These results indicate that the acetylation-induced FASN destabilization is mediated by the ubiquitin-proteasome system. Supporting this notion, we found markedly increased levels of polyubiquitylated FASN-Flag in HEK293T cells following TSA treatment, but not NAM treatment (Figs. S1C and 2D). Moreover, FASN polyubiquitylation is further increased by TSA treatment in combination with MG132 in these cells (Fig. 2E). The TSA-dependent increase in endogenous FASN acetylation and polyubiquitylation, and the accompanying reduction in FASN protein level in HEK293T cells (Fig. 2F), further support the idea that acetylation promotes FASN polyubiquitylation and protein destabilization.

Additionally, we also compared the acetylation levels of ubiquitylated and non-ubiquitylated FASN. HEK293T cells ectopically expressing FASN-Flag and HA-Ub were treated with TSA for 16 hours and following treatment, cell lysates were subjected to three sequential immunoprecipitations; first with Flag beads to precipitate total FASN proteins, then with HA antibody to enrich ubiquitylated FASN, and finally with FASN antibody to precipitate the non-ubiquitylated FASN from the supernatant depleted by the HA antibody (Fig. S1D). Compared with non-ubiquitylated FASN, we found that ubiquitylated FASN was more heavily acetylated (Fig. S1D), further confirming the role of acetylation in promoting FASN polyubiquitylation.

KAT8 is a major acetyltransferase of FASN

The acetylation state of a protein is controlled by lysine acetyltransferases (KATs) and deacetylases (KDACs), enzymes that catalyze the addition and removal of an acetyl group from a lysine residue, respectively. To identify potential KAT(s) which are responsible for FASN acetylation, we ectopically expressed a panel of 12 different human KAT proteins and determined their interaction with endogenous FASN in HEK293T cells. Among the KATs tested, only KAT8 was found to interact with endogenous FASN (Figs. 3A and S2). Reciprocal immunoprecipitation confirmed the protein interaction between endogenous FASN and Myc-KAT8 (Fig. 3B). Overexpression of Myc-KAT8 increased the acetylation level of endogenous FASN by 2.2-fold (Fig. 3C). In contrast, knockdown of *KAT8* decreased endogenous FASN acetylation by as much as 55% (Fig. 3D). Consistent with our

earlier observation that acetylation promotes FASN protein degradation (Figs. 1D and 1E), we found that overexpression of Myc-KAT8 decreased the steady state level of endogenous FASN protein by 59% without a significant change in *FASN* mRNA expression in HEK293T cells (Fig. 3E). Conversely, *KAT8* knockdown increased endogenous FASN protein level by 1.45-fold, again without significantly affecting *FASN* mRNA level (Fig. 3F). These results collectively indicate that KAT8 is a major acetyltransferase of FASN.

HDAC3 is a major deacetylase of FASN

Our earlier observation that TSA, but not NAM, increases FASN acetylation (Fig. 1A) led us to search for the HDAC family enzyme(s) that is involved in FASN deacetylation. We transiently expressed 9 of 11 human HDAC proteins in combination with FASN-Flag and determined their interaction (Figs. 4A and S3A). Among the tested HDACs, only HA-HDAC3 was found to interact with FASN-Flag. Consistent with this result, the protein interaction between endogenous HDAC3 and FASN was readily detected in HEK293T cells (Fig. 4B). Likewise, overexpression of HA-HDAC3 decreased the acetylation level of endogenous FASN by 35% in HEK293T cells, while the expression of a catalytic inactive mutant HDAC3^{Y298H} (38) failed to reduce FASN acetylation (Fig. 4C). Conversely, *HDAC3* knockdown increased the acetylation level of endogenous FASN by >1.5-fold in HEK293T cells (Fig. S3B). In HEK293T cells with stable *HDAC3* knockdown, the half-life of endogenous FASN protein was shortened by 4 hours (Fig. S3C). Surprisingly, the steady state level of FASN protein was largely unchanged (Figs. S3B). We found that *FASN* mRNA expression was increased by as much as 3-fold in HEK293T cells depleted for *HDAC3* (Fig. S3B), which is in line with a previous report that deletion of *HDAC3* leads to up-regulated *FASN* mRNA expression in mouse liver cells (39).

To provide direct evidence that the catalytic activity of HDAC3 regulates FASN protein stability, we treated cells with RGFP966, a selective inhibitor for HDAC3 (40). RGFP966 selectively inhibits HDAC3 with IC₅₀ of 0.08 μM, but it is much weaker toward other HDACs such as HDAC1 and HDAC2 whose activity was not significantly affected by RGFP966 concentration of up to 15 μM (40). Our data demonstrated that RGFP966 increased the polyubiquitylation levels of both ectopically expressed and endogenous FASN proteins in HEK293T cells in a dose-dependent manner, with a significant increase in FASN polyubiquitylation in cells treated with 10 μM RGFP966 (Figs. 4D and 4E). Accordingly, RGFP966 treatment decreased endogenous FASN protein levels in a dose-dependent manner with a notable reduction (49%) at 10 μM RGFP966, but without modulating *FASN* mRNA expression in HEK293T cells (Fig. 4F). The effects of RGFP966 on stimulating endogenous FASN polyubiquitylation and subsequent protein degradation were also detected in HCT116 cells (Figs. S3D and S3E). Collectively, these data support a critical role of HDAC3 in deacetylating FASN and thus protecting FASN from degradation.

Acetylation promotes FASN interaction with TRIM21 E3 ubiquitin ligase

To elucidate the mechanism underlying acetylation-dependent FASN polyubiquitylation and protein degradation, we established a HEK293T cell line that stably expressed FASN N-terminally tagged with both Flag and streptavidin-binding peptide (SBP). Tandem affinity purification followed by mass spectrometry analysis (TAP-MS) allowed us to identify

potential interacting partners of FASN (Supplementary Table S2). Among these FASN-interacting proteins, TRIM21 (also known as RNF81, Ro52, and SSA1) which is a RING domain E3 ubiquitin ligase (41), DDB1 and SMU1 which are components of the CUL4A and CUL4B-based E3 ubiquitin ligase complexes, FBXO22 which is a substrate-recognition component of the SCF (SKP1-CUL1-F-box)-type E3 ubiquitin ligase complex, and CUL5 E3 ubiquitin ligase were identified. Next, we transiently co-expressed FASN-Flag, HA-Ub, and Myc-tagged CUL1, CUL4A, CUL4B, CUL5, and TRIM21, and found that Myc-TRIM21, but not cullin proteins, substantially increased the polyubiquitylation level of FASN-Flag (Figs. S4A and S4B). Furthermore, ectopic expression of TRIM21 increased the polyubiquitylation level of endogenous FASN in HCT116 cells (Fig. S4C). The association of endogenous FASN with either ectopically expressed or endogenous TRIM21 was confirmed by western blot analyses, and importantly, the FASN-TRIM21 association is enhanced by treatment with HDAC inhibitors in either 293T or HCT116 cell (Figs. 5A, 5B and S4D). Ectopic expression of wild-type TRIM21, but not the catalytically inactive RING deletion mutant TRIM21, reduced endogenous FASN protein level by 43% in HEK293T cells (Fig. 5C). Conversely, *TRIM21* knockout increased endogenous FASN protein levels by >1.5-fold in stable HEK293T cells (Fig. 5D) without altering *FASN* mRNA expression. In addition, we also found that either MG132 or TSA treatment substantially enhanced the increased level of polyubiquitylated FASN-Flag in HEK293T cells ectopically expressing Myc-TRIM21 (Fig. 5E). Notably, the effect of TSA or RGFP966 on enhancing FASN polyubiquitylation was abolished by *TRIM21* deletion in HEK293T cells (Figs. 5F). Together, these results indicate that acetylation enhances FASN interaction with its E3 ubiquitin ligase TRIM21, thereby promoting FASN polyubiquitylation and destabilization.

Acetylation of FASN inhibits *de novo* lipogenesis and tumor cell growth

FASN is essential for *de novo* fatty acid synthesis to support cancer cell growth (15). Inhibition of *de novo* fatty acid synthesis causes cell apoptosis and suppresses tumor cell growth (14, 42). We therefore investigated the role of FASN acetylation in regulating *de novo* lipogenesis and cell proliferation. When HCT116 cells were treated with TSA and RGFP966, we found that the level of endogenous FASN was reduced by 40% and 49%, respectively (Fig. 6A). These reductions in FASN protein led to decreased FASN activity in whole cell lysate by 50% and 60%, respectively, as measured by spectrophotometrically recorded oxidation of NADPH (Fig. 6A). Stimulated Raman Scattering (SRS) microscope has been applied to analyze biological components within cells and tissues by mapping the distribution of diverse biochemical components (35). [ENREF 1](#) Here, we employed a hyperspectral femtosecond SRS microscope to detect the lipid content in HCT116 cells upon treatment with TSA or RGFP966. The Raman signals at 2850 and 2928 cm^{-1} (S2850 and S2928) reflect the lipid and protein contents, respectively (Figs. S5A and S5B). We found in HCT116 cells that the ratio of S2850/S2928 was markedly decreased by 7.93% ($P=0.02$) and 10.2% ($P=0.0079$), after TSA and RGFP966 treatment, respectively (Fig. 6B), suggesting that broad inhibition of HDAC enzymes or selective inhibition of HDAC3 reduce intracellular lipid content. Importantly, ectopic expression of FASN rescued the decrease in lipid content caused by either TSA or RGFP966 treatment (Fig. 6B and S5C), supporting the notion that FASN acetylation inhibits *de novo* lipogenesis in cancer cells.

Stable expression of FASN-Flag and treatment with HDAC3 inhibitor RGFP966 resulted in significant increase and decrease of HCT116 cell proliferation (Fig. 6C and S5C). The cell proliferation stimulatory effect of FASN was blunted by RGFP966 treatment (Fig. 6C). The same effects of FASN overexpression and HDAC3 inhibitor on cell proliferation were also observed in ZR-75-30 breast cancer cells (Fig. S5C and Fig. 6E). RGFP966 treatment in both cell lines resulted in decreased levels of FASN protein (Figs. 6D and 6F). Taken together, these results support the notion that inhibition of HDAC3 promotes FASN protein degradation, thereby decreasing *de novo* lipogenesis and cell proliferation in a cell type independent manner.

Acetylation of FASN is downregulated in HCC tumors

Hepatocellular carcinoma cancer (HCC) is one of the most common tumors worldwide (43). FASN is highly expressed in many human cancers, including liver cancer (3). Our findings that acetylation promotes FASN degradation and inhibits the ability of FASN to support cancer cell proliferation prompted us to examine both acetylation and total protein levels of FASN in human liver cancers. We carried out direct immunoblot analysis of a panel of 17 pairs of primary HCC tumors and their adjacent normal tissues. This analysis revealed that the acetylation level of FASN was invariably reduced in all HCC tumor tissues tested when compared to adjacent normal tissues (Figs. 7A, S6A, and 7C). Of these 17 pairs of samples, 14 tumor samples exhibited a significant increase in the steady-state level of FASN protein, while 3 tumor samples had reduced FASN protein levels compared to their corresponding normal tissues (Figs. 7A, S6B, and 7B). Interestingly, most of the tested HCC tumors (15 of 17 pairs) exhibited increased HDAC3 protein expression compared to adjacent normal tissues (Figs. 7A, S6B, and 7D). Finally, our data demonstrate that FASN protein levels had a negative correlation with FASN acetylation levels in HCC tumors and adjacent normal tissues ($R^2=0.1510$, $P=0.0231$) (Fig. 7E), and HDAC3 protein levels had a positive correlation with FASN protein levels in HCC tumors and adjacent normal tissues ($R^2=0.1596$, $P=0.0192$) (Fig. 7F). Furthermore, FASN protein levels had no significant association with either KAT8 (Figs. 7A, and S6B) or TRIM21 (Figs. S6C–F) in HCC tumors and adjacent normal tissues. Collectively, these data indicate that acetylation of FASN is frequently downregulated in HCC tumors, which is at least in part associated with increased HDAC3. Thus, FASN acetylation and HDAC3 may be potential biomarkers for HCC tumors.

Discussion

Reprogramming of metabolic pathways is a hallmark of cancer (15, 44). Proliferating cancer cells require continuous *de novo* fatty acids synthesis to provide precursors for membrane biogenesis. Deregulated *de novo* lipogenesis causes abnormal accumulation of fatty acids, affects signal transduction and gene expression, and eventually influence tumor cell survival. FASN, as one of the rate-limiting enzymes in the *de novo* lipogenesis pathway, has been found to be overexpressed in a wide variety of human cancers by multiple mechanisms (2, 7, 9, 45). For instance, *FASN* gene expression is controlled by SREBP-1, which is the major transcriptional regulator of *FASN* and is up-regulated by hypoxia in solid tumors (19); Isopeptidase USP2a interacts with and stabilizes FASN by deubiquitinating and preventing

its proteasomal degradation (45). In this study, we uncovered a novel biochemical mechanism of FASN regulation at the post-transcriptional level. Our data demonstrate that KAT8 catalyzes FASN acetylation which then promotes FASN interaction with TRIM21 E3 ubiquitin ligase, leading to subsequent polyubiquitylation and proteasomal degradation. Conversely, HDAC3-mediated deacetylation of FASN contributes to increased FASN protein and elevated *de novo* fatty acid synthesis in tumor cells (Fig. 7G).

TRIM21 belongs to the tripartite motif (TRIM) family and acts as a RING finger domain-containing E3 ligase (41). Several reported substrates of TRIM21 are all involved in innate and adaptive immunity, including IRF3, IRF5, IRF7, IRF8, and SQSTM1/p62 (41, 46–50). Results from our study demonstrate that FASN is a novel substrate of TRIM21. We show that TRIM21 physically interacts with and ubiquitylates FASN to regulate its protein stability. Additionally, our data revealed that FASN acetylation enhanced its interaction with TRIM21. It will be interesting to determine how TRIM21-mediated FASN ubiquitylation affects cellular immunity and other non-proliferative property of the cell.

Our study also shows that HDAC3 inhibitor RGFP966 increases FASN acetylation and destabilizes FASN protein, supporting a critical role for HDAC3-regulated FASN acetylation in the control of *de novo* lipid synthesis and the regulation of tumor cell growth/survival. We found that in primary hepatocellular carcinoma cancer samples, the acetylation level of FASN is frequently reduced, and both FASN and HDAC3 protein levels are up-regulated when compared to adjacent normal tissues. These findings indicate that HDAC3 may function as an oncogenic factor with a potential role in deacetylating and stabilizing FASN, thereby promoting *de novo* lipid synthesis to support rapid cancer cell growth. These findings suggest that HDAC3 inhibitors may merit exploration as a therapeutic agent for cancers such as HCC.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Grant support

This work was supported by the MOST 973 Program (grant No. 2012CB910303 to D. Ye, 2012CB910101 to K.-L. Guan), the NSFC grants (grant No. 81372198 and 81522033 to D. Ye), the NSFC Program of International Cooperation and Exchanges (grant No. 81120108016 to L.-X. Qin and Y. Xiong), and the Shanghai Committee of Science and Technology, China (grant No. 14QA1400600 and 16JC1404000 to D. Ye). This work was also supported by NIH grants (GM067113 and CA063834 to Y. Xiong, CA196878 and GM51586 to K.-L. Guan).

We thank members of the Fudan MCB laboratory for discussions and support throughout this study. We thank Liu-Lin Xiao and Shu-Fen Li from Prof. Xi Li's Lab (Fudan University) for offering technical support, and Prof. Jia-Huai Han's lab (Xiamen University) for offering cDNA plasmids of *KATs*, and Matt Smith (University of North Carolina) for reading the manuscript.

References

1. Rashid A, Pizer ES, Moga M, Milgraum LZ, Zahurak M, Pasternack GR, et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. *The American journal of pathology*. 1997; 150:201–8. [PubMed: 9006336]

2. Gansler TS, Hardman W 3rd, Hunt DA, Schaffel S, Hennigar RA. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. *Human pathology*. 1997; 28:686–92. [PubMed: 9191002]
3. Hao Q, Li T, Zhang X, Gao P, Qiao P, Li S, et al. Expression and roles of fatty acid synthase in hepatocellular carcinoma. *Oncology reports*. 2014; 32:2471–6. [PubMed: 25231933]
4. Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21/WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. *Int J Oncol*. 2004; 24:591–608. [PubMed: 14767544]
5. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. *Future oncology*. 2010; 6:551–62. [PubMed: 20373869]
6. Van de Sande T, Roskams T, Lerut E, Joniau S, Van Poppel H, Verhoeven G, et al. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. *The Journal of pathology*. 2005; 206:214–9. [PubMed: 15880754]
7. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. *International journal of cancer Journal international du cancer*. 2002; 98:19–22. [PubMed: 11857379]
8. Pflug BR, Pecher SM, Brink AW, Nelson JB, Foster BA. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model. *The Prostate*. 2003; 57:245–54. [PubMed: 14518031]
9. Menendez JA, Lupu R, Colomer R. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/ neu-overexpressing human breast cancer cells to docetaxel (taxotere). *Breast cancer research and treatment*. 2004; 84:183–95. [PubMed: 14999148]
10. Takahiro T, Shinichi K, Toshimitsu S. Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2003; 9:2204–12. [PubMed: 12796387]
11. Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE, Kuhajda FP. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. *Cancer research*. 1996; 56:2745–7. [PubMed: 8665507]
12. Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR, Kuhajda FP. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. *Cancer research*. 1996; 56:1189–93. [PubMed: 8640795]
13. Fako VE, Zhang JT, Liu JY. Mechanism of Orlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase. *ACS catalysis*. 2014; 4:3444–53. [PubMed: 25309810]
14. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. *Cancer research*. 2004; 64:2070–5. [PubMed: 15026345]
15. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nature reviews Cancer*. 2007; 7:763–77. [PubMed: 17882277]
16. da Silva Xavier G, Rutter GA, Diraison F, Andreolas C, Leclerc I. ChREBP binding to fatty acid synthase and L-type pyruvate kinase genes is stimulated by glucose in pancreatic beta-cells. *J Lipid Res*. 2006; 47:2482–91. [PubMed: 16891625]
17. Gosmain Y, Dif N, Berbe V, Loizon E, Rieusset J, Vidal H, et al. Regulation of SREBP-1 expression and transcriptional action on HKII and FAS genes during fasting and refeeding in rat tissues. *J Lipid Res*. 2005; 46:697–705. [PubMed: 15627654]
18. Griffin MJ, Sul HS. Insulin regulation of fatty acid synthase gene transcription: roles of USF and SREBP-1c. *IUBMB life*. 2004; 56:595–600. [PubMed: 15814457]
19. Furuta E, Pai SK, Zhan R, Bandyopadhyay S, Watabe M, Mo YY, et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. *Cancer research*. 2008; 68:1003–11. [PubMed: 18281474]
20. Wolf G. Nutritional and hormonal regulation of fatty acid synthase. *Nutrition reviews*. 1996; 54:122–3. [PubMed: 8710241]
21. Griffin MJ, Wong RHF, Pandya N, Sul HS. Direct interaction between USF and SREBP-1c mediates synergistic activation of the fatty-acid synthase promoter. *Journal Of Biological Chemistry*. 2007; 282:5453–67. [PubMed: 17197698]

22. Latasa MJ, Moon YS, Kim KH, Sul HS. Nutritional regulation of the fatty acid synthase promoter in vivo: sterol regulatory element binding protein functions through an upstream region containing a sterol regulatory element. *Proceedings of the National Academy of Sciences of the United States of America*. 2000; 97:10619–24. [PubMed: 10962028]
23. Swinnen JV, Heemers H, Deboel L, Fougelle F, Heyns W, Verhoeven G. Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. *Oncogene*. 2000; 19:5173–81. [PubMed: 11064454]
24. Katsurada A, Iritani N, Fukuda H, Matsumura Y, Nishimoto N, Noguchi T, et al. Effects of nutrients and hormones on transcriptional and post-transcriptional regulation of fatty acid synthase in rat liver. *European journal of biochemistry / FEBS*. 1990; 190:427–33.
25. Ma GY, Gove CD, Hems DA. Effects of glucagon and insulin on fatty acid synthesis and glycogen degradation in the perfused liver of normal and genetically obese (ob/ob) mice. *The Biochemical journal*. 1978; 174:761–8. [PubMed: 31866]
26. Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. *Int J Oncol*. 2004; 24:1369–83. [PubMed: 15138577]
27. Fukuda H, Iritani N, Sugimoto T, Ikeda H. Transcriptional regulation of fatty acid synthase gene by insulin/glucose, polyunsaturated fatty acid and leptin in hepatocytes and adipocytes in normal and genetically obese rats. *European Journal Of Biochemistry*. 1999; 260:505–11. [PubMed: 10095788]
28. Xiong Y, Guan KL. Mechanistic insights into the regulation of metabolic enzymes by acetylation. *Journal Of Cell Biology*. 2012; 198:155–64. [PubMed: 22826120]
29. Choudhary C, Weinert BT, Nishida Y, Verdin E, Mann M. The growing landscape of lysine acetylation links metabolism and cell signalling. *Nature reviews Molecular cell biology*. 2014; 15:536–50. [PubMed: 25053359]
30. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, et al. Regulation of cellular metabolism by protein lysine acetylation. *Science*. 2010; 327:1000–4. [PubMed: 20167786]
31. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. *Science*. 2009; 325:834–40. [PubMed: 19608861]
32. Lundby A, Lage K, Weinert BT, Bekker-Jensen DB, Secher A, Skovgaard T, et al. Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns. *Cell Rep*. 2012; 2:419–31. [PubMed: 22902405]
33. Lin R, Tao R, Gao X, Li T, Zhou X, Guan KL, et al. Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. *Molecular cell*. 2013; 51:506–18. [PubMed: 23932781]
34. Jiang W, Wang S, Xiao M, Lin Y, Zhou L, Lei Q, et al. Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. *Molecular cell*. 2011; 43:33–44. [PubMed: 21726808]
35. Ji M, Lewis S, Camelo-Piragua S, Ramkissoon SH, Snuderl M, Venneti S, et al. Detection of human brain tumor infiltration with quantitative stimulated Raman scattering microscopy. *Science translational medicine*. 2015; 7:309ra163.
36. Avalos JL, Bever KM, Wolberger C. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. *Molecular cell*. 2005; 17:855–68. [PubMed: 15780941]
37. David M, Vigushin SA, Pace Paul E, Mirsaidi Nina, Ito Kazuhiro, Adcock Ian, Charles Coombes R. Trichostatin A Is a Histone Deacetylase Inhibitor with Potent Antitumor Activity against Breast Cancer in Vivo. *Clinical Cancer Research*. 2001; 7:971–6. [PubMed: 11309348]
38. Lahm A, Paolini C, Pallaoro M, Nardi MC, Jones P, Neddermann P, et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104:17335–40. [PubMed: 17956988]

39. Sun Z, Feng D, Fang B, Mullican SE, You SH, Lim HW, et al. Deacetylase-independent function of HDAC3 in transcription and metabolism requires nuclear receptor corepressor. *Molecular cell*. 2013; 52:769–82. [PubMed: 24268577]
40. Malvaez M, McQuown SC, Rogge GA, Astarabadi M, Jacques V, Carreiro S, et al. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. *Proceedings of the National Academy of Sciences of the United States of America*. 2013; 110:2647–52. [PubMed: 23297220]
41. Espinosa A, Zhou W, Ek M, Hedlund M, Brauner S, Popovic K, et al. The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. *J Immunol*. 2006; 176:6277–85. [PubMed: 16670339]
42. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. *Cancer research*. 2003; 63:3799–804. [PubMed: 12839976]
43. Siegel R, Naishadham D, Jemal A. *Cancer statistics, 2012*. *CA: a cancer journal for clinicians*. 2012; 62:10–29. [PubMed: 22237781]
44. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. *Nutrition*. 2000; 16:202–8. [PubMed: 10705076]
45. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. *Cancer cell*. 2004; 5:253–61. [PubMed: 15050917]
46. Higgs R, Lazzari E, Wynne C, Gabhann JN, Espinosa A, Wahren-Herlenius M, et al. Self Protection from Anti-Viral Responses-Ro52 Promotes Degradation of the Transcription Factor IRF7 Downstream of the Viral Toll-Like Receptors. *PLoS one*. 2010;5.
47. Espinosa A, Dardalhon V, Brauner S, Ambrosi A, Higgs R, Quintana FJ, et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by deregulating the IL-23-Th17 pathway. *J Exp Med*. 2009; 206:1661–71. [PubMed: 19635858]
48. Higgs R, Gabhann JN, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. *J Immunol*. 2008; 181:1780–6. [PubMed: 18641315]
49. Kong HJ, Anderson DE, Lee CH, Jang MK, Tamura T, Taylor P, et al. Cutting edge: Autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. *J Immunol*. 2007; 179:26–30. [PubMed: 17579016]
50. Pan JA, Sun Y, Jiang YP, Bott AJ, Jaber N, Dou Z, et al. TRIM21 Ubiquitylates SQSTM1/p62 and Suppresses Protein Sequestration to Regulate Redox Homeostasis. *Molecular cell*. 2016; 61:720–33. [PubMed: 26942676]




Figure 1. Acetylation promotes FASN protein degradation

(A) HEK293T cells overexpressing FASN were treated without or with control solvent, NAM (5 mM, 6 hours) and/or TSA (0.5 mM, 16 hours). Acetylation levels of immunopurified FASN-Flag were determined by Western blot using a pan-anti-acetyllysine antibody (α -AcK). IP denotes immunoprecipitation. Relative FASN acetylation was normalized by Flag protein.

(B) Endogenous FASN protein was immunoprecipitated with an anti-FASN antibody from the indicated cells treated with control solvent alcohol or TSA (0.5 mM, 16 hours). Acetylation levels of endogenous FASN were determined by Western blot.

(C) Quantification of acetylation levels of endogenous FASN in the indicated cell lines in (B). Relative FASN acetylation ratios were calculated after normalizing against total FASN protein.

(D) The indicated cells were treated with control solvent alcohol or TSA (0.5 mM, 16 hours), followed by Western blot to determine endogenous FASN protein levels.

(E) Quantification of endogenous FASN protein levels in the indicated cell lines in (D). Relative FASN protein levels were normalized by β -actin.

(F) The indicated cells were treated with control solvent alcohol or TSA (0.5 mM, 16 hours), followed by qRT-PCR to determine endogenous *FASN* mRNA expression. Shown are average values with standard deviation (S.D.) of triplicated experiments.

*Denotes $P < 0.05$, and **denotes $P < 0.01$ for the indicated comparison; n.s. = not significant.




Figure 2. Acetylation promotes FASN protein polyubiquitylation and destabilization

(A) HCT116 cells were pre-treated with control solvent alcohol or TSA (0.5 mM, 4 hours), and then subjected to CHX treatment (10 μ g/ml) for the indicated time course. Endogenous FASN protein level was analyzed by Western blot (left). Quantification of endogenous FASN protein levels are shown (right).

(B) HEK293T cells were treated with MG132 (10 μ M) for the indicated time course. Endogenous FASN protein level was analyzed by Western blot. Relative FASN protein levels were normalized by β -actin.

(C) HEK293T cells were treated with control solvent alcohol or TSA (0.5 μ M) in the absence or presence of MG132 (10 μ M). Endogenous FASN protein level was analyzed by Western blot, normalized by β -actin protein (top). Please note that the protein levels of endogenous FASN or β -actin in lane 1/2 and lane 3 were determined on the same blot. Quantification of endogenous FASN protein levels are shown (bottom). Shown are average values with standard deviation (S.D.) of triplicated experiments.

(D–E) Polyubiquitylation levels of affinity purified FASN-Flag proteins were detected by Western blot in transfected HEK293T cells under treatment with control solvent, NAM and/or TSA in the absence (D) or presence (E) of MG132 (10 μ M, 6 hours).

(F) Polyubiquitylation, acetylation, and the protein levels of endogenous FASN in HEK293T cells under treatment with control solvent alcohol or TSA (0.5 mM, 16 hours) were detected by Western blot.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 3. KAT8 is a major acetyltransferase of FASN

(A–B) Interaction between the indicated Myc-tagged KAT proteins and endogenous FASN was detected by Western blot.

(C) Increased amount of Myc-KAT8 was transiently overexpressed in HEK293T cells, and then acetylation levels of endogenous FASN proteins were determined.

(D) Stable HEK293T cells with *KAT8* knockdown were generated by retroviral infection, and the knockdown efficiency was determined by qRT-PCR (bottom). Acetylation levels of endogenous FASN were detected by Western blot (top).

(E) Myc-KAT8 was transiently overexpressed in HEK293T cells, and then mRNA and protein levels of endogenous FASN were determined by qRT-PCR and western blot, respectively. Relative FASN protein levels were normalized by β -actin.

(F) In stable HEK293T cells with *KAT8* knockdown, mRNA and protein levels of endogenous FASN were determined by qRT-PCR and western blot, respectively. Shown are average values with standard deviation (S.D.) of triplicated experiments.




Figure 4. HDAC3 is a major acetyltransferase of FASN

(A) Flag-tagged FASN was overexpressed in HEK293T cells in combination with different HA-tagged HDACs as indicated. Flag-FASN protein was immunopurified, followed by Western blot to detect its interaction with HA-tagged HDACs.

(B) In HEK293T cells, FASN protein was immunopurified with FASN antibody, followed by Western blot to detect HDAC3 interaction.

(C) HA-tagged wild-type HDAC3 or its catalytically inactive mutant HDAC3^{Y298H} was expressed in HEK293T cells. FASN protein was immunopurified with FASN antibody, followed by Western blot to detect its acetylation.

(D) Flag-tagged FASN and HA-tagged Ub plasmids were co-overexpressed in HEK293T cells, which were then subjected to increased concentrations of RGFP966 as indicated. FASN protein was immunopurified with Flag beads, followed by Western blot to detect FASN polyubiquitylation with a HA antibody.

(E) HEK293T cells were subjected to increased concentrations of RGFP966 as indicated. Endogenous FASN was immunopurified, followed by Western blot to detect its acetylation and ubiquitylation levels.

(F) HEK293T cells were subjected to increasing concentrations of RGFP966 or TSA as indicated. Endogenous FASN mRNA and protein levels were determined by qRT-PCR and

Western blot, respectively. Shown are average values with standard deviation (S.D.) of triplicated experiments.

(F) FASN-Flag and HA-Ub were co-overexpressed in *TRIM21* knockout HEK293T cell pools and control cells. The transfected cells were treated with control solvents, TSA (0.5 mM, 16 hours) or RGFP966 (10 μ M, 24 hours). FASN-Flag protein was immunopurified, followed by Western blot to detect FASN polyubiquitylation with a HA antibody.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 6. Acetylation of FASN inhibits *de novo* lipogenesis and suppresses tumor cell growth
(A) HCT116 cells were treated with control solvents, TSA (0.5 mM, 16 hours) or RGFP966 (10 μ M, 24 hours). FASN activity in the whole cell lysates were measured (right). FASN protein was immunopurified, followed by Western blot to detect its acetylation. Relative FASN protein levels were normalized by β -actin.
(B) HCT116 cells stably expressing empty vector or FASN were treated as mentioned in (A). Lipid content was measured and quantified by employing a SRS microscope as described in ‘Method’.
(C–F) HCT116 or ZR-75-30 cells stably expressing empty vector or FASN were seeded in 6-well plates, and were treated with control solvent DMSO or RGFP966 (10 μ M) as indicated. Cell numbers were counted every day over a period of 5 days (C and E). At day 5, cells were harvested, and the acetylation and protein levels of FASN were determined by Western blot (D and F). Relative FASN protein levels were normalized by β -actin.




Figure 7. Acetylation of FASN is downregulated in human hepatocellular cancers

(A) In total, 17 pairs of tumor tissues (T) and adjacent normal tissues (N) were lysed. FASN protein was immunopurified with FASN antibody, followed by Western blot to detect its acetylation. Protein levels of FASN, HDAC3, and KAT8 were determined by direct Western blot. Relative FASN and HDAC3 protein levels were normalized by β -actin. Shown are 5 pairs of samples. See Figure S6 for the other 12 pairs of samples.

(B–D) Quantification of relative FASN protein, FASN acetylation, and relative HDAC3 protein levels in the 17 pairs of samples tested.

(E–F) Correlation between FASN protein levels and its acetylation levels (E) or HDAC3 protein levels (F) in the tested 17 pairs of samples.

Shown are average values with standard deviation (S.D.). Statistical analyses were performed with a two-tailed paired *t*-test. *Denotes $P < 0.05$, **denotes $P < 0.01$, and ***denotes $P < 0.001$ for the indicated comparison.

(G) Shown is a working model depicting how acetylation promotes FASN protein degradation through the ubiquitin-proteasome pathway, thereby inhibiting *de novo* lipogenesis.